Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia

Fig. 4

a Up-regulate NDRG2 protein expression NDRG2 protein levels after transfection with miRNA inhibitors (including miR-28-5p, miR-650 and NC miRNA inhibitors) in 2 primary CLL cells (Western blot analysis) (CLL1: CLL cells from a patient with p53 deletion; CLL2: CLL cells from a patient without p53 aberrations); b In CLL primary cells, miR-28-5p and miR-650 inhibitors treated groups show significantly increased NDRG2 protein level compared to NC (median level, 0.8341 vs. 0.1252, P < 0.001; 0.7621 vs. 0.1252, P < 0.001). c Up-regulated NDRG2 protein expression in CLL cells from patients without p53 aberrations after transfection with miR-28-5p inhibitor (P = 0.018) and miR-650 inhibitor (P = 0.005). d Up-regulated NDRG2 protein expression in CLL cells from patients with p53 aberrations after transfection with miR-28-5p inhibitor (P = 0.011) and miR-650 inhibitor (P = 0.025)

Back to article page